Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

Real-World Treatment Patterns of Large B-Cell Lymphoma Patients Over Time in a Post-CAR T Approval Era

Rapid Increase in Blood CD19 CAR-T Vector Load during the First five Days Post Infusion Is Associated with Severe ICANS

Incidence of Cytokine Release Syndrome and Neurological Events in Patients With Relapsed or Refractory Large B-Cell Lymphoma at and Beyond 2 Weeks Following Axicabtagene Ciloleucel Infusion

A United States (US) Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Compared to Odronextamab in Third Line or Later (3L+) Diffuse Large B-Cell Lymphoma

Time to CAR T infusion in local versus distant treatment centers

In vitro and in vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, including a Dysfunctional CD8+ T Cell State Characterized by the GATA3 overexpression

Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) in Patients With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)